Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series-Reference-Cited by-同舟云学术

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series

Published:2020-07 Issue:1 Volume:83 Page:46-52
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Abdat Rana,Waldman Reid A.,de Bedout Valeria,Czernik Annette,Mcleod Michael,King Brett,Gordon Samantha,Ahmed Razzaque,Nichols Anna,Rothe Marti,Rosmarin David

Funder

AbbVie

Celgene

Dermavant

Dermira

Janssen

Lilly

Novartis

Pfizer

Regeneron Pharmaceuticals

Sanofi

Sun Pharmaceuticals

Bristol-Myers Squibb

Incyte

Merck

Publisher

Elsevier BV

Subject

Dermatology

Reference12 articles.

1. Bullous pemphigoid;Miyamoto;An Bras Dermatol,2019

2. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management;Amber;Clin Rev Allergy Immunol,2018

3. Review of autoimmune blistering diseases: the pemphigoid diseases;Daniel;J Eur Acad Dermatol Venereol,2019

4. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations;Kridin;Immunol Res,2018

5. Dupilumab for the treatment of recalcitrant bullous pemphigoid;Kaye;JAMA Dermatol,2018

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Bullous pemphigoid combined with Sjögren’s syndrome complicated by central nervous system infection;Frontiers in Immunology;2024-09-10

2. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review;Journal of Clinical Medicine;2024-08-16

3. Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus;Frontiers in Immunology;2024-08-05

4. Treatment of Epidermolysis bullosa acquisita with dupilumab;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-08-02

5. Radiotherapy-induced localized bullous pemphigoid with a favorable response to dupilumab;JAAD Case Reports;2024-06